


Clean Copy of the Pending Claims

21 ~~4.~~ A compound having the general structure:




wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

2
~~5.~~ The compound of claim ~~4~~ wherein R_7 and R_8 are H;
 R_1 is H or F; and
 R_3 is hydroxy or $-OCONH_2$.


~~6.~~ A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound represented by the formula



wherein R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.


7. The method of claim 6 wherein said compound has the general structure



wherein R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and R_3 is hydroxy or $-OCONH_2$.


8. The method of claim 7 wherein R_9 is H or halo; and R_3 is $-OCONH_2$.

9. A method for preventing or limiting tissue damage resulting from an ischemic event, said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and R_3 is hydroxy or $-OCONH_2$.

10. The method of claim 9 wherein said compound has the general structure



wherein R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and R_3 is hydroxy or $-OCONH_2$.


- Q1
11. The method of claim 10 wherein R_9 is H or halo; and R_3 is $-\text{OCONH}_2$.
12. The method of claim 9 wherein the tissue damage is caused by cerebral ischemia.
13. The method of claim 9 wherein the tissue damage is caused by myocardial ischemia.
14. A pharmaceutical composition comprising a compound selected from the group consisting of



wherein R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-\text{OCONH}_2$; and
a pharmaceutically acceptable carrier.

- 12
15. The composition of claim 14 wherein said compound has the general structure




wherein R_9 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and
 R_3 is hydroxy or $-\text{OCONH}_2$.

¹³
~~16.~~ The composition of claim ~~18~~¹² wherein R₉ is halo.

¹⁴
~~17.~~ The composition of claim ~~15~~¹² wherein R₉ is H or F; and
R₃ is -OCONH₂.

¹⁵
~~18.~~ The composition of claim ~~16~~¹² wherein R₉ is H or F; and
R₃ is hydroxy.

³
~~19.~~ A compound having the general structure:



wherein R₁, R₇, R₈, R₉ and R₁₀ are independently selected from the group
consisting of H, halo, alkyl, haloalkyl, -NR₅R₆, hydroxy, and alkoxy;

R₂ is F or Cl;

R₃ is hydroxy or -OCONH₂; and

R₅ and R₆ are independently C₁-C₄ alkyl.

⁴
~~20.~~ The compound of claim ~~19~~³ wherein

R₁ and R₇ are independently selected from the group consisting of H, halo, alkyl,
haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₈, R₉ and R₁₀ are H.

⁵
~~21.~~ The compound of claim ~~19~~³ wherein
R₁ and R₈ are independently selected from the group consisting of H, halo, alkyl,
haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₇, R₉ and R₁₀ are H.

⁶
~~22.~~ The compound of claim ~~19~~³ wherein
R₁ is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;
R₂ is F;
R₃ is hydroxy or -OCONH₂; and
R₇, R₈, R₉ and R₁₀ are H.


⁷
~~23.~~ The compound of claim ~~22~~⁶ wherein
R₁ is selected from the group consisting of H, F, Cl, CF₃ and hydroxy.

⁸
~~24.~~ The compound of claim ~~23~~⁷ wherein
R₁ is F.

⁹
~~25.~~ A pharmaceutical composition comprising the compound of claim ~~19~~³ and a
pharmaceutically acceptable carrier.

¹⁰
~~26.~~ A pharmaceutical composition comprising the compound of claim ~~22~~⁶ and a
pharmaceutically acceptable carrier.

27. A method for reducing the incidence and severity of an epileptic seizure in an individual, said method comprising the step of administering to said individual a compound represented by the general structure:



wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂.

28. The method of claim 27 wherein R₁ is H or F, and R₇ and R₈ are H.

29. The method of claim 28 wherein R₃ is -OCONH₂.